{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer", "query": { "condition": "Advanced Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9634, "total_pages": 964, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T11:44:14.243Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00607113", "title": "Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Avastin", "type": "DRUG" }, { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2008-01", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00607113" }, { "nct_id": "NCT04068896", "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Metastatic Castration-resistant Prostate Cancer", "Bladder Cancer", "Melanoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Gastric Cancer", "Esophageal Cancer", "Ovarian Cancer", "Head Neck Squamous Cell Carcinoma", "Prostate Cancer" ], "interventions": [ { "name": "NGM120 30mg", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg", "type": "BIOLOGICAL" }, { "name": "NGM120 30mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg Q3W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2019-10-16", "completion_date": "2024-01-08", "has_results": true, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 20, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068896" }, { "nct_id": "NCT05383170", "title": "A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Breast Cancer", "Advanced Melanoma" ], "interventions": [ { "name": "CyPep-1", "type": "DRUG" }, { "name": "Pembrolizumab 25 MG/ML [KEYTRUDA®]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytovation AS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-03-21", "completion_date": "2024-09-23", "has_results": true, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05383170" }, { "nct_id": "NCT05018273", "title": "Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, Adult" ], "interventions": [ { "name": "VB10.NEO", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nykode Therapeutics ASA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-12-21", "completion_date": "2024-10-09", "has_results": false, "last_update_posted_date": "2024-12-03", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 5, "location_summary": "San Francisco, California • New Haven, Connecticut • Louisville, Kentucky + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05018273" }, { "nct_id": "NCT00005941", "title": "Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Vaginal Cancer" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "64 Years", "sex": "FEMALE", "summary": "Up to 64 Years · Female only" }, "enrollment_count": null, "start_date": "1999-11", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005941" }, { "nct_id": "NCT00877474", "title": "Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ADVANCED SOLID TUMORS" ], "interventions": [ { "name": "PM01183", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2009-03", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877474" }, { "nct_id": "NCT03212274", "title": "Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Glioblastoma", "Recurrent Cholangiocarcinoma", "Recurrent Glioma", "Recurrent Malignant Solid Neoplasm", "WHO Grade 2 Glioma", "WHO Grade 3 Glioma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2019-01-30", "completion_date": "2026-07-28", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 51, "location_summary": "Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03212274" }, { "nct_id": "NCT06260774", "title": "Study of TTX-MC138 in Subjects With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "TTX-MC138", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TransCode Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2024-09-05", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 4, "location_summary": "Dallas, Texas • Houston, Texas • West Valley City, Utah + 1 more", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06260774" }, { "nct_id": "NCT02926690", "title": "Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer" ], "interventions": [ { "name": "OTS167PO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoTherapy Science, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-05-29", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 8, "location_summary": "Norwalk, Connecticut • Atlanta, Georgia • Honolulu, Hawaii + 4 more", "locations": [ { "city": "Norwalk", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02926690" }, { "nct_id": "NCT01465659", "title": "Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Alpha Cell Carcinoma", "Pancreatic Beta Islet Cell Carcinoma", "Pancreatic Delta Cell Carcinoma", "Pancreatic G-cell Carcinoma", "Recurrent Islet Cell Carcinoma" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "pazopanib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2011-12-12", "completion_date": "2021-01-27", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-06-07T11:44:14.243Z", "location_count": 5, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01465659" } ] }